Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncology pipeline
Coherus BioSciences (CHRS) continues to experience high short interest and volatile trading as investors assess its oncology and biosimilar portfolios. The company, a US biotechnology firm, is strategically shifting towards high-margin oncology assets while managing its legacy biosimilar products. Investors are closely monitoring clinical trial data, regulatory milestones, and market dynamics to gauge the company's future financial performance and competitive position.
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
Coherus Oncology reported its first-quarter 2026 financial results, highlighting LOQTORZI® net revenue of $11.8 million, a 61% increase year-over-year. The company also provided updates on its pipeline, including the completion of patient accrual for the 1L HCC Phase 2 clinical trial for casdozokitug and progress in the tagmokitug development program. Coherus ended the quarter with $167.0 million in cash, cash equivalents, and marketable securities.
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
Coherus Oncology announced its first-quarter 2026 financial results, reporting $11.8 million in LOQTORZI net revenue, a 61% increase year-over-year. The company provided updates on its oncology pipeline, including the completion of patient accrual for the casdozokitug Phase 2 trial and advancements in the tagmokitug program. Coherus ended the quarter with $167.0 million in cash, cash equivalents, and marketable securities.
Earnings call transcript: Coherus BioSciences Q1 2026 revenue misses forecast
Coherus BioSciences reported Q1 2026 revenue of $12.31 million, falling short of the $14.43 million forecast, but its EPS of -$0.25 met expectations. Despite the revenue miss, the company's shares rose 11.43% in after-hours trading, driven by investor optimism about future growth and strategic initiatives. Key products like LOQTORZI showed significant year-over-year growth, and management expects a rebound from weather-related impacts in Q2 2026.
Coherus BioSciences Inc CHRS
This page provides an overview of Coherus BioSciences Inc. (CHRS) stock, including its current price, market cap, and P/E ratio. It shows the stock closed at $1.950 with an 11.43% increase on May 11th. The platform also offers various financial analysis tools and news for investors.
Coherus (CHRS) Reports Q1 Revenue Below Expectations
Coherus BioSciences (CHRS) announced Q1 revenue of $12.31 million, falling short of the anticipated $14.34 million. The company, which has a GF Score™ of 51/100, is focusing on its LOQTORZI product for neuroendocrine prostate cancer and other pipeline products, despite facing challenges in financial strength and profitability. Investors are advised to be cautious due to the revenue shortfall, low GF Score™, and minimal insider activity.
Coherus Oncology (CHRS) grows Q1 2026 revenue as losses narrow and cash hits $167M
Coherus Oncology reported a notable increase in Q1 2026 revenue to $12.3 million from $7.6 million year-over-year, primarily driven by LOQTORZI sales totaling $11.8 million. The company successfully narrowed its GAAP net loss from continuing operations to $36.9 million and maintained a cash position of $167.0 million, signaling progress in its oncology transition while continuing development for key pipeline candidates like tagmokitug and casdozokitug.
Coherus Biosciences Inc (CHRS) Stock News & Articles
This page provides an overview of Coherus BioSciences Inc (CHRS), a biopharmaceutical company specializing in biosimilars and immuno-oncology treatments. It details the company's key products like UDENYCA, CIMERLI, and YUSIMRY, and highlights its strategic partnerships aimed at affordable healthcare solutions. The page also features a recent article discussing Wall Street analyst research calls, including one relevant to Coherus Oncology.
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
Coherus Oncology, Inc. announced it will release its first quarter 2026 financial results after market close on Monday, May 11, 2026. The company's management will host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a business update. A replay of the webcast will be available on the investors section of their website.
Satterfield reports 6.93M shares in Coherus Oncology (NASDAQ: CHRS) ownership filing
Thomas A. Satterfield, Jr. has filed a Schedule 13G/A, reporting beneficial ownership of 6.93 million shares, or 4.6%, of Coherus Oncology (NASDAQ: CHRS) common stock. This includes shares held jointly, through various entities he controls, and via limited powers of attorney for other holders. The filing details both sole and shared voting/dispositive power over these shares.
Coherus Oncology announces proposed public offering of common stock
Coherus BioSciences announced a proposed public offering of its common stock. The offering is subject to market and other conditions. All shares are to be offered by Coherus, and a lead book-running manager, Cantor, along with Oppenheimer & Co., are acting as book-running managers.
[DEF 14A] Coherus Oncology, Inc. Definitive Proxy Statement
Coherus Oncology, Inc. has filed a definitive proxy statement (DEF 14A) for its virtual 2026 annual meeting on May 27, 2026. Stockholders will vote on director elections, auditor ratification, executive compensation, a one-time stock option repricing, and an increase in the equity incentive pool. The Board recommends voting "FOR" all proposals, emphasizing the importance of equity incentives for retention and aligning employee interests with stockholders.
Coherus Oncology (CHRS) proposes option repricing and 7.7M-share increase
Coherus Oncology (CHRS) has filed a preliminary proxy statement for its 2026 Annual Meeting, proposing a one-time repricing of 9.54 million employee and consultant stock options and a 7.7 million share increase to its 2014 Equity Incentive Award Plan. The option repricing aims to restore incentive by resetting exercise prices to the closing price on the meeting date, with an extension of terms, while the share increase is crucial for talent attraction and retention in its transition to an oncology company. The Board recommends a "FOR" vote on all proposals, asserting they are in the best interest of the company and stockholders.
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Hold" by Brokerages
Coherus Oncology, Inc. (NASDAQ:CHRS) has received an average "Hold" recommendation from five research firms, with analysts providing one sell, one hold, and three buy ratings. The average 1-year target price for the stock is $5.5125. Major institutional investors and hedge funds hold 72.82% of the company's stock, and Coherus Oncology recently reported Q4 earnings per share of ($0.34), missing analyst expectations.
Coherus Biosciences (CHRS) Is One of the Best Penny Stocks, Here is Why
Coherus Oncology Inc. (NASDAQ: CHRS) is identified as a top penny stock with potential to triple money, following its Q4 2025 earnings report. The company showed progress with increased LOQTORZI sales and significant debt reduction, signaling a transition towards an oncology-focused business. Management anticipates further growth through revenue, partnerships, and clinical catalysts in 2026 for its immunotherapy pipeline.
If You Invested $1,000 in Coherus (CHRS)
This article analyzes the historical performance of a $1,000 investment in Coherus (CHRS) over 1, 5, and 10 years, detailing significant losses over the longer terms and underperformance against the S&P 500. It also provides an overview of Coherus Oncology, Inc.'s focus on developing and commercializing antibody-based cancer therapies, highlighting its key product LOQTORZI and pipeline candidates like CHS-114 and casdozokitug. The company's strategic emphasis on combination therapies for various solid tumors and its corporate information are also discussed.
Metastatic Hepatocellular Carcinoma Clinical Trial Pipeline
DelveInsight's report highlights significant advancements in the Metastatic Hepatocellular Carcinoma (HCC) pipeline, with over 20 companies and 25+ pipeline drugs in development. Key clinical trial updates include Coherus Oncology Inc.'s Phase 2 trial for SRF388 and AstraZeneca's Phase I/II study for AZD5851. The report details several promising emerging drugs like CS1003, Casdozokitug, TTI-101, and ST316, emphasizing the robust research efforts to address this challenging cancer.
Coherus Oncology announces proposed public offering of common stock
Coherus BioSciences, Inc. (CHRS) announced a proposed public offering of its common stock. The offering will be underwritten by Jefferies and TD Cowen as joint book-running managers. The company intends to grant the underwriters a 30-day option to purchase additional shares.
Coherus BioSciences Q4 2025 earnings preview
This article provides an earnings preview for Coherus BioSciences' Q4 2025 results. Investors will be looking for key metrics such as EPS, revenue, and any guidance provided for the upcoming year. The article's main purpose is to inform readers about the impending financial report.
Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of "Hold" from Analysts
Coherus Oncology, Inc. (NASDAQ:CHRS) has received a consensus "Hold" recommendation from five research firms, with an average one-year price target of $5.51. Oppenheimer recently initiated coverage with an "Outperform" rating and a $10.00 target. The company's shares are trading at $1.69 after missing quarterly EPS and revenue estimates, and analysts forecast a full-year EPS of approximately -1.05.
Coherus BioSciences Q4 2025 earnings preview
This article provides a Q4 2025 earnings preview for Coherus BioSciences. It likely discusses expectations for the company's financial performance in the upcoming earnings report.
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform
Oppenheimer has reiterated an Outperform rating and a $10.00 price target for Coherus Biosciences (NASDAQ:CHRS), highlighting the stock's recent rebound and undervalued status despite fourth-quarter 2025 sales missing consensus. The firm remains optimistic about the company's pipeline opportunities, particularly with key readouts scheduled for 2026 and plans to expand Loqtorzi's market footprint. Recent financial maneuvers, including a public offering and a clinical supply agreement, further support Oppenheimer's positive outlook.
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform
Oppenheimer has reiterated an Outperform rating and $10.00 price target for Coherus Biosciences (NASDAQ:CHRS), highlighting the company's strong pipeline opportunity and the stock's undervaluation. Despite some earlier weakness, Coherus Biosciences has seen a significant rebound, with shares surging 36% year-to-date, driven by anticipated key readouts in 2026 for its Loqtorzi and tagmokitug programs. The firm believes the market is underappreciating Coherus's potential, especially with planned investments in commercial infrastructure and recent financial and strategic maneuvers like a public offering and a clinical supply agreement with Johnson & Johnson.
COHERUS BIOSCIENCES ($CHRS) Releases Q4 2025 Earnings
COHERUS BIOSCIENCES ($CHRS) reported its Q4 2025 earnings, with an EPS of -$0.34, beating estimates by $0.02, but revenue of $12,750,000 missed estimates by over $1.4 million. Following the report, the company's stock price decreased by 6.15% since market close. The article also details recent hedge fund activity, showing significant decreases in holdings by some institutional investors while others substantially increased their positions.
Coherus Oncology Q4 2025 Results: Quarterly Loss, Annual Profit - News and Statistics
Coherus Oncology reported a loss of $37.6 million in its fourth quarter of 2025, or 31 cents per share, which adjusted to 34 cents per share. The drug developer's revenue for the quarter was $12.7 million, missing Street forecasts. However, for the entire year, the company posted a profit of $168 million, or $1.43 per share, with total revenue reaching $42.2 million.
Coherus BioSciences (CHRS) Q4 Earnings Preview: What to Expect
Coherus BioSciences (CHRS) is expected to report a significant decline in EPS and revenue for Q4, with analysts forecasting -$0.31 EPS and $14.09 million in revenue. The biotechnology company, focusing on oncology, shows financial distress indicators like a negative Altman Z-Score and declining revenue growth. Despite the financial challenges, its strategic focus on expanding the oncology pipeline offers potential long-term growth, though near-term risks remain significant.
Coherus BioSciences's Earnings Outlook
Coherus BioSciences (NASDAQ: CHRS) is expected to release its quarterly earnings report on March 9, 2026, with an estimated EPS of $-0.34. The company's financial health shows notable revenue growth of 91.19% and a strong net margin of -307.07%, despite a high debt-to-equity ratio and lower-than-average market capitalization. Shares have increased by 68.75% over the last 52 weeks, heading into the earnings release.
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
Coherus Oncology, Inc. (Nasdaq: CHRS) announced it will release its full-year and fourth-quarter 2025 financial results on Monday, March 9, 2026, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update. A webcast replay and related materials will be available on the investor relations section of their website.
Coherus Oncology, Inc. to Release 2025 Financial Results on March 9, 2026, with Conference Call to Follow
Coherus Oncology, Inc. announced it will release its full year and fourth quarter 2025 financial results on March 9, 2026, after market close, followed by a conference call and webcast at 4:30 p.m. Eastern Time. The company, focused on oncology with its approved PD-1 inhibitor LOQTORZI®, will discuss the results and provide a business update, with a webcast replay available on its website. This release highlights the company's commitment to transparency and stakeholder engagement while providing an overview of its pipeline candidates.
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
Coherus Oncology, Inc. announced it will release its full year and fourth quarter 2025 financial results after market close on Monday, March 9, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update. The company is a commercial-stage oncology firm with an approved PD-1 inhibitor, LOQTORZI, and a pipeline of clinical candidates targeting various cancers.
Coherus investor talks stream online from Boston and Miami
Coherus Oncology (NASDAQ: CHRS) announced that its senior management will present at two investor conferences in March 2026: the TD Cowen Healthcare Conference in Boston on March 4, 2026, and the Citizens Life Sciences Conference in Miami on March 10, 2026. Webcasts and replays of these presentations will be available for approximately 90 days on the company's investor events calendar. The news of these presentations led to a mild negative market reaction, with CHRS declining 0.61% on the day this information was published.
FDA Approves Delivery System of Biosimiliar Pegfilgrastim-cbqv for Febrile Neutropenia
The FDA has approved Udencya Onbody, an on-body injector (OBI) presentation of the biosimilar pegfilgrastim-cbqv for cancer patients to reduce infection incidence from febrile neutropenia after chemotherapy. Developed by Coherus BioSciences, this delivery system offers an automatic administration option, featuring an indicator, status light, auditive signal, and a retractable needle to enhance patient safety and convenience. Commercial availability is expected in the first quarter of 2024, providing patients and physicians with more flexible administration choices.
Sandoz completes acquisition of Coherus's ranibizumab biosimilar
Sandoz has finalized its acquisition of Coherus BioSciences’ CIMERLI ophthalmology franchise, including the biologics license application, product inventory, and commercial software access. This strategic move strengthens Sandoz's biosimilar portfolio and expands its offerings for U.S. patients with vision impairment. Coherus offloaded the product to better focus on its oncology investments and reduce debt.
Coherus closes $50.1 million public offering of common stock
Coherus Oncology, Inc. successfully closed a public offering, raising approximately $50.1 million through the sale of 28.6 million shares at $1.75 each. The proceeds will fund the commercialization of LOQTORZI, clinical development, and general corporate purposes, as the company transitions from a biosimilar firm to a clinical-stage oncology biotech. Despite recent stock volatility and anticipated sales decline by analysts, Coherus has significantly reduced its debt and shows strong price momentum over the last six months.
Oncology biotech Coherus raises $50M for LOQTORZI and clinical programs
Coherus Oncology (NASDAQ: CHRS) has closed an underwritten public offering of 28.6 million common shares at $1.75 per share, generating approximately $50.1 million in gross proceeds. The company plans to use these funds to support the commercialization of its PD-1 inhibitor LOQTORZI, advance its clinical development programs, and for general corporate purposes. This financing was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments, and Samsara BioCapital.
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of "Hold" by Analysts
Coherus Oncology, Inc. (NASDAQ:CHRS) has received an average "Hold" rating from analysts, with a 12-month average price target of $5.5125. Recent analyst actions include Oppenheimer initiating coverage with an "outperform" rating and a $10.00 price target, alongside a recent upgrade from "sell" to "hold" by Wall Street Zen. The company's stock has recently traded down 19.9% and institutional investors hold 72.82% of its shares.
Coherus Oncology prices stock offering to raise $50.1M
Coherus BioSciences announced the pricing of an underwritten public offering of 33.4 million shares of its common stock at $1.50 per share, aiming to raise $50.1 million before underwriting discounts and commissions. The offering also includes warrants to purchase up to 33.4 million additional shares. This financial move is expected to close around February 20, 2026, and is subject to standard closing conditions.
Coherus BioSciences stock falls after pricing $50.1 million share offering
Coherus BioSciences Inc. (NASDAQ:CHRS) stock tumbled 14.5% in premarket trading after announcing the pricing of a public offering for 28.6 million shares at $1.75 each, a significant discount to its previous closing price. The offering is expected to raise $50.1 million in gross proceeds, intended to support the commercialization of its oncology treatment LOQTORZI, advance product candidate development, and for general corporate purposes. The offering is anticipated to close around February 17, 2026.
Coherus BioSciences Prices $50.1 Million Share Offering
Coherus BioSciences announced the pricing of a $50.1 million share offering. The company is a commercial-stage biopharmaceutical firm focused on developing cancer immunotherapies, with a pipeline including several antibody immunotherapy candidates.
Coherus Oncology prices $50.1 million public offering of common stock
Coherus Oncology has priced an underwritten public offering of 28.6 million shares of common stock at $1.75 per share, aiming to generate approximately $50.1 million in gross proceeds. The company plans to use these proceeds for the commercialization of LOQTORZI, continued clinical development of product candidates, and general corporate purposes. This follows other recent news, including a clinical supply agreement with Johnson & Johnson and Oppenheimer reiterating an Outperform rating on Coherus stock.
Coherus Oncology Prices Public Offering at $1.75 per Share
Coherus Oncology announced a public offering of 28.6 million shares at $1.75 each, aiming to raise approximately $50.1 million. The proceeds will fund the commercialization of LOQTORZI®, continued clinical development, and general corporate purposes. Underwriters TD Cowen, Guggenheim Securities, and Oppenheimer & Co. have a 30-day option to purchase an additional 4.29 million shares.
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
Coherus Oncology, Inc. (NASDAQ: CHRS) has announced the pricing of an underwritten public offering of 28,600,000 shares of its common stock at $1.75 per share, aiming to raise approximately $50.1 million before underwriting discounts. The company plans to use the net proceeds to support the commercialization of LOQTORZI®, advance clinical development of other product candidates, and for general corporate purposes. The offering is expected to close around February 17, 2026, with TD Cowen, Guggenheim Securities, and Oppenheimer & Co. acting as joint bookrunners.
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
Coherus Oncology, Inc. announced the pricing of an underwritten public offering of 28,600,000 shares of its common stock at $1.75 per share, expecting gross proceeds of approximately $50.1 million. The company plans to use the net proceeds for the commercialization of LOQTORZI®, clinical development of product candidates, and general corporate purposes. The offering is anticipated to close around February 17, 2026, with TD Cowen, Guggenheim Securities, and Oppenheimer & Co. acting as joint bookrunners.
Coherus plans stock sale to fund LOQTORZI commercialization
Coherus Oncology (NASDAQ: CHRS) announced a proposed underwritten public offering of its common stock to fund the commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of product candidates, and for general corporate purposes. This offering includes a 30-day option for underwriters to purchase up to 15% additional shares and is subject to market conditions. Following the news, Coherus' stock declined by 15.92%, reflecting investor concern over potential dilution.
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
Coherus Oncology, Inc. announced a proposed underwritten public offering of its common stock, with an option for underwriters to purchase additional shares. The company plans to use the net proceeds to support the commercialization of LOQTORZI®, further clinical development of its product candidates, and for general corporate purposes. The offering is subject to market conditions and will be made through a filed shelf registration statement.
Analysts’ Top Healthcare Picks: Coherus Biosciences (CHRS), Pfizer (PFE)
Two healthcare companies, Coherus Biosciences (CHRS) and Pfizer (PFE), have received bullish analyst ratings. H.C. Wainwright reiterated a Buy rating for Coherus Biosciences with a $7.00 price target, while Oppenheimer initiated coverage with a Buy rating and a $10.00 price target. CMB International Securities maintained a Buy rating on Pfizer with a $35.46 price target, and TipRanks – DeepSeek upgraded the stock to Buy with a $29.00 price target.
Oppenheimer initiates Coherus Biosciences stock with Outperform rating
Oppenheimer has initiated coverage on Coherus Biosciences (NASDAQ:CHRS) with an Outperform rating and a $10.00 price target, suggesting a significant upside of 529%. The firm highlighted the oncology company's strong pipeline, including its lead anti-CCR8 antibody tagmokitug and anti-IL-27 antibody casdozokitug, along with an existing approved PD-1 backbone. Coherus is also noted for its low revenue valuation multiple despite being profitable with a P/E ratio of 3.02.
Coherus Oncology Surges 30% Following Oppenheimer’s Outperform Rating
Coherus Oncology Inc. (CHRS) saw its stock surge by over 20% following an "Outperform" rating from Oppenheimer, which set a $10 price target. Despite this positive catalyst and promising results for its investigational anti-CCR8 antibody, the company faces significant financial hurdles, including negative margins and declining revenue. Investors are advised to exercise cautious optimism, balancing the potential of the therapeutic pipeline against current financial instabilities.
Coherus BioSciences Shares Surge on Analyst Initiation and Capital Move
Shares of Coherus BioSciences surged following an "Outperform" rating initiation by Oppenheimer & Co. with a $10 price target, driven by anticipated 2026 clinical data readouts. Concurrently, the biopharmaceutical firm filed a prospectus to potentially raise up to $64.9 million, aiming to strengthen its liquidity. The sustainability of this rally will depend on forthcoming clinical trial results and the strategic deployment of the capital raise.
Coherus BioSciences Shares Surge on Analyst Initiation and Capital Move
Coherus BioSciences experienced a significant share surge following Oppenheimer's "Outperform" rating and the company's filing for a potential equity offering of up to $64.9 million. The rally is driven by anticipated clinical data readouts in 2026 for its drug candidates, tagmokitug and Loqtorzi, and the company's strategic move to capitalize on positive market sentiment. The sustainability of this momentum will depend on upcoming clinical trial results and the effective use of the raised capital.
